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Abstract. The study assessed changes in hemodynamic and biochemical parameters, vascular age 
and 5-year cardiovascular risk on the background of complex pharmacotherapy in patients with 
stable angina I-III functional class (FC), hypertension of I-III degree, chronic heart failure (CHF) 
II-III FC taking into account the influence of exogenous and pharmacogenetic factors. The study 
included 200 patients aged 45 – 65 years with concomitant cardiovascular diseases: hypertension 
of I-III degree, stable angina (I-III FC), with CHF (II-III FC). Patients of the 1st group (100 
patients) received prestans, carvedilol, hydrochlorothiazide, verospiron, preparations of 
acetylsalicylic acid, atorvastatin. Patients of the 2nd group (100 patients) received monopril 
(fosinopril sodium), carvedilol, amlodipine, hydrochlorothiazide, verospiron, preparations of 
acetylsalicylic acid, atorvastatin. 
In hypertensiology part of the study to the end of the observation period the positive dynamics of 
the main hemodynamic parameters found in both groups. The main indicators of lipid spectrum 
were improved. Assessment of the impact of pharmacogenetic factors on the effectiveness of the 
therapy showed no influence of ACE gene polymorphisms (rs4344) and CYP2D6 gene 
(rs1135840) for the basic hemodynamic parameters, whereas carriers of the genotype (G;G) of 
the gene CETP (rs4783961) in both groups was associated with a less significant increase of 
cholesterol of high density lipoproteins (HDL cholesterol) compared with carriers of the allele 
(A;A) and (A;G). The significant improvement noted in the analysis of the data of vascular age as 
an integral indicator of the state of the cardiovascular system, as well as a 5-year cardiovascular 
risk on the background of the combined pharmacotherapy. . However, there were not detected 
statistically significant differences between 1-St and 2-nd groups  
Keywords: coronary heart disease, hypertension, heart failure, pharmacogenetic, lipid-transport 
system, the vascular age.  
Introduction. Cardiovascular diseases are 
currently the subject of intense study because, despite 
significant advances in prevention and therapy, they 
remain one of the main causes of death and disability in 
most socially developed countries in the world [1, 2]. 
The main goal of treatment of patients with 
arterial hypertension (AH), coronary heart disease 
(CHD) is to reduce the risk of cardiovascular 
complications and death from them. To achieve this 
goal requires not only reduction in blood pressure 
(BP) to the target level, but the correction of all 
modifiable risk factors, and treatment of associated 
diseases  – diabetes mellitus (DM), CHF, etc. In turn, 
the persistent commitment of these patients for 
continued medical treatment and lifestyle changes is 
a major factor in the success of treatment of chronic 
cardiovascular diseases [3, 4]. 
The term "vascular age” was developed a few 
years ago to promote the patient adherence to a 
permanent treatment and conscious self-control in the 
outpatient setting. This term allows the patient to 
present a risk of future disease and complications, 
expressed in years, not percentages that are more 
clear and accessible for most patients who do not 
have the medical education [5]. A modified scale 
SCORE (score 10-year risk of cardiovascular death) 
was the basis for the calculation. The modified scale 
SCORE for determining “vascular age” (VA) allows 
to focus on the individual exogenous risk factors of 
cardiovascular diseases and their complications 
(smoking, blood pressure, blood glucose, total 
cholesterol and high-density lipoproteins) [6, 7]. 
Strong and significant correlation of the percentages 
of the risk of cardiovascular complications with a 
calculated value of "vascular age" has already been 
demonstrated in some studies [8]. 
"Vascular age" could potentially be reduced, 
since among its components are modified, exogenous 
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indicators (blood pressure, smoking, levels of total 
cholesterol, lipoproteins of blood serum). 
Consequently, the motivation to lower your “vascular 
age” for a few years with smoking cessation, 
modification of diet and constant medication is likely 
to be the most effective for the Russian patient [9]. 
The question of the influence of genetic factors 
controlling the pharmacokinetics and 
pharmacodynamics of drugs, on the efficacy of 
pharmacotherapy is also being actively discussed in the 
world in recent years. Personalized medicine originated 
in the depths of clinical pharmacology has become one 
of the most promising approaches in optimizing 
pharmacotherapy of socially significant diseases. The 
successes  of molecular biology, in particular, the 
sequencing of the human genome, has allowed and will 
allow in the future to identify the genes governing the 
functioning of body systems and determining the 
efficacy and safety of pharmacological interventions 
[10]. Thus, the pharmacogenetic approach is the most 
modern among the methods of personalized medicine 
and improves the efficiency and increase safety of 
treatment of cardiovascular disease, determining the 
prognosis of treatment. Unfortunately, only a few 
pharmacogenetic tests approved for use in the Russian 
Federation and in the world today, that are rarely used 
in clinical practice [11, 12]. The latter makes it relevant 
as a search for new alleles responsible for the 
pharmacokinetics and pharmacodynamics of drugs, and 
testing of pharmacogenetic studies have already 
identified the “alleles –candidates” in real clinical 
practice [13, 14]. In particular, the testing of 
pharmacogenetic tests in routine clinic allows you to 
answer the questions of whether genotyping for already 
proposed in world literature the alleles given the 
potential benefits from such testing, including the 
economic viability [15, 16, 17]. 
It should be noted that neither the methodology 
of "vascular age" or the methodology of 
pharmacogenetic personalization of comorbid 
pathology in the conditions of unorganized 
population not tested and possible benefit from their 
use is still under discussion, both at the international 
and Russian level. On the one hand, the dynamics of 
indicators of "vascular age" under the influence of 
the most commonly applied schemes of combination 
pharmacotherapy has not been studied. On the other 
hand, data on the use of pharmacogenetic testing in 
conditions typical practices only begin to accumulate 
in the scientific community. All of the above makes it 
relevant to the topic undertaken for the study. 
The purpose of this study was to investigate the 
dynamics of the indicator of “vascular age” based on 
the modified SCORE scale and the 5-year vascular 
risk scale ASCORE in the composition of a 
comprehensive assessment of the various schemes of 
combined pharmacotherapy in patients with 
concomitant cardiac pathology, given the exogenous 
and pharmacogenetic factors. 
Research tasks: 
1) evaluation of the effectiveness of a 6-month
combined therapy using a variety of angiotensin 
converting enzyme inhibitors (ACE-I) (perindopril 
arginine and fosinopril) in achieving the target BP 
values in patients with uncontrolled hypertension and 
concomitant cardiac pathology; 
2) evaluation of the effect of 6-month combined
therapy on lipid level: total cholesterol, high density 
lipoproteins (HDL) and low density lipoproteins (LDL), 
triglycerides (TG), creatinine and glucose serum;  
3) assessment of the impact of pharmacogenetic
factors, carriage of allelic variants of genes involved in 
the pharmacokinetics and pharmacodynamics of 
antihypertensive and hypolipidemic drugs on key 
indicators of cardiovascular and lipid-transport systems; 
4) the calculation of the indicator "vascular age"
definition of a 5-year risk of complications on a scale 
ASCORE and assessment of impact of combined 
therapy on these parameters in patients after 6 
months of treatment. 
Materials and methods. 
The study included 200 patients aged 45 – 65 years 
with concomitant cardiovascular diseases: hypertension 
of I-III degree, stable angina (I-III FC), with CHF (II-III 
FC). Patients with myocardial infarction suffering for 
less than 6 months, acute coronary syndrome, unstable 
angina, arrhythmias, CHF terminal (IV FC), valvular 
heart defects, history of stroke, chronic obstructive 
pulmonary disease, DM of the 1st type or the 
decompensated 2nd type DM, pregnancy, patients who 
had serious cardiovascular disease or condition that 
affects duration of life (need for dialysis, cancer, drugs, 
etc.) were excluded from the study. 
All patients randomized into two groups. 
The main clinical characteristics of the study 
groups are presented in table 1. 
Table1 
Clinical characteristics of study groups 
Parameter 1st group 2nd group 
The number of 
patients 
• Men
• Women
100 
48 
52 
100 
54 
46 
Average age, years 
60,5 ± 4,3 56,04±6,7 
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Patients of the 1st group (100 patients) received 
a fixed combination of ACE inhibitors and calcium 
channel blocker (CCB) – prestans (perindopril 
arginine in a dose of 5-10 mg/day and amlodipine 5-
10 mg/day), carvedilol at a dose of 12.5-50 mg/day, 
hydrochlorothiazide – 12,5-25 mg/day, verospiron 25 
mg/day, acetylsalicylic acid drugs– 75 – 100 mg/day, 
atorvastatin at a dose of 20-40 mg/day. 
Patients of the 2nd group (100 patients) received 
monopril (fosinopril sodium) at a dose of 10-40 
mg/day, carvedilol in the dose 12,5-50 mg/day, 
amlodipine 5-10 mg/day, hydrochlorothiazide – 12,5-
25 mg/day, verospiron 25 mg/day, acetylsalicylic 
acid drugs– 75 – 100 mg/day, atorvastatin 20-40 
mg/day. 
The criteria for titration of the doses of medicine 
were the target levels of hemodynamic, clinical and 
laboratory parameters. 
The observation period was 6 months. 
"Vascular age" was calculated by the modified 
SCORE table, taking into account gender, age, smoking 
status, blood pressure and total cholesterol of blood 
serum [5]. 5-year risk of cardiovascular complications 
was calculated on a scale ASCORE [5]. 
Pharmacogenetic testing for allelic variants of the 
genes was carried out in pharmacogenetic laboratory of 
the сenter for preclinical and clinical studies, national 
research university "BelSU", Belgorod, Russia. DNA 
extraction was performed using the reagents set 
ThermoFisherScientific 250 discharge, to assess the 
quality and quantity of obtained DNA was used, the 
system Qubit with the set of necessary reagents. 
Pharmacogenetic typing for alleles was conducted in 
real time with the use of high-performance systems 
FluidigmBioMark™ HD System using a standard set of 
boot reagents, customized set of synthesized primers 
and a universal chip format is 48x48. Processing of the 
obtained results was performed in the software package 
BiomarkDataAnalisys licensed to work in the 
laboratory [18].  
Statistical data processing was carried out by 
methods of parametric and non-parametric statistics 
using Statistica 8.0. Differences were considered 
significant at values of bilateral p<0.05. Presenting the 
results of the parametric statistics used the format 
M±SD. 
The results of the study and their discussion. 
Combined therapy was well tolerated by all 
patients. The drugs cancellation and adverse drug 
reactions were not recorded. 
In hypertensiological part of the study the 
positive dynamics of the main hemodynamic 
parameters were found in both groups by the end of 
the observation period (table 2). Patients in the 
intervention groups achieved the target levels for 
heart rate (HR) and blood pressure (BP) in result of 
titration of drug doses in all areas of 
pharmacotherapy. 
Table 2 
Change hemodynamic variables in groups of 
observations on the background of treatment  
(M±SD, n = 200) 
Parameter 
1st group (n=100) 2nd group (n=100) 
At 
baseline 
After 6 
months 
At 
baseline 
After 6 
months 
Systolic 
BP, mm 
Hg. 
152,7±10,9 134,2±7,6* 154,3±9,5 135,2±8,9* 
Diastolic 
BP, mm 
Hg 
92,2±7,6 81,1±6,3* 91,8±7,1 81,4±4,8* 
HR, 
beats/min 
74,3±6,5 65,9±4,0* 72,6±4,2 64,8±3,5* 
Note: here and in table 4 the significance of 
differences of indicators in the process of treatment: * – p< 
0.05, * * – p< 0,01. 
Further analysis of the changes in hemodynamic 
parameters did not reveal statistically significant 
differences (p > 0.05) between the groups (table 3). It 
says comparable antihypertensive efficacy of the 
proposed regimens, but also emphasizes their 
sufficiency in absolute terms. 
Table 3 
Comparative analysis of efficiency of used 
pharmacotherapeutic schemes for changing the basic 
hemodynamic parameters (M±SD, n = 200) 
Hemodynamic 
parameters 
1st group 
(n=100) 
2nd group 
(n=100) 
∆Systolic BP (%) 10,9±5,8 12,2±4,3 
∆Diastolic BP (%) 10,9±7,1 10,2±7,5 
∆ HR (%) 8,9±4,5 10,7±4,4 
Seemed interesting to assess in practice the 
influence of allelic variants of genes involved in the 
pharmacokinetics and pharmacodynamics of drugs 
on the efficacy of pharmacotherapy.  The impact of 
the allelic variant of the gene is a target of ACE 
inhibitors – ACE allele (A/G) (rs4344) on the 
effectiveness of combination therapy containing ACE 
inhibitors – perindopril – in the 1st group, and 
fosinopril – in the 2nd group respectively were 
estimated . Choice of single nucleotide 
polymorphism rs 4344 caused, on the one hand, a 
small study of this polymorphism among alleles of 
the gene for the ACE, and on the other hand, 
contradictory data about its influence on the 
antihypertensive efficacy and safety of drugs that 
inhibit this enzyme [19, 20]. Comparative analysis of 
efficiency of used drug regimens subject to the 
carriage of allelic variants of the studied 
polymorphisms is presented in table 4. 
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Table 4 
Comparative analysis of effectiveness of pharmacotherapy depending on the carriage of allelic variants 
of the gene ACE (rs4344) (M±SD, n=200) 
Group 1st group (n=100) 2nd group (n=100) 
Allele 
rs4344 (А;A), 
(n=23) 
rs4344 (А;G), 
(n=55) 
rs4344 (G;G), 
(n=22) 
rs4344 (А;A), 
(n=26) 
rs4344 (А;G), 
(n=53) 
rs4344 
(G;G), 
(n=21) 
∆ Systolic BP, 
mm Hg. 
18,2±6,5 16,8±7,8 18,8±7,5 19,8±+7,6 19,5±7,9 19,4±7,4 
∆ Diastolic BP, 
mm Hg 
11,3±6,2 9,4±5,2 11,8±6,5 9,8±5,6 9,4±5,4 9,5±4,0 
∆ HR, beats/min 7,2±2,5 7,0±2,9 7,1±2,8 9,8±6,6 9,8±6,2 9,4±5,1 
Note: Difference between groups on relevant allelic variants in all hemodynamic parameters was not revealed. 
In the analysis of the data, within group genotypes 
(A;A), (A;G), (G;G), nor between groups on relevant 
allelic variants of statistically significant differences 
was not obtained (in all cases, the values of the two-way 
p > 0.05). This is consistent with some of the literature 
data about the absence of a clinically significant effect 
of this polymorphism for the realization of the 
hypotensive effect of ACE inhibitors. 
Further seemed interesting to assess the 
influence of genetic factors on the implementation of 
another drug included in the scheme of 
pharmacotherapy in both groups of observation – 
carvedilol. It is well known that a major enzyme 
determining the pharmacokinetics, and as a 
consequence, the effectiveness of most beta-blockers 
is the cytochrome CYP2D6. The literature describes 
the impact of a number of alleles of this cytochrome 
on the efficacy and safety of pharmacotherapy with 
beta blockers. One of the most promising for the 
study is single nucleotide polymorphism rs 1135840 
gene cytochrome CYP2D6, since in several studies it 
has been shown as sufficient frequency of mutant 
alleles, and its impact on the effectiveness of beta-
blockers [21, 22]. In our study, we have attempted to 
evaluate the impact in terms of the Russian 
population (table 5). 
Table 5 
Comparative analysis of effectiveness of regimens depending on the carriage of allelic variants of CYP2D6 gene 
(rs1135840), (M±SD, n=200) 
Group 1st group (n=100) 2nd group (n=100) 
Allele 
rs1135840 
(G;G), (n=81) 
rs1135840 
(G;C), (n=10) 
rs1135840 
(C;C), (n=9) 
rs1135840 
(G;G), (n=79) 
rs1135840 
(G;C), (n=11) 
rs1135840 
(C;C), (n=10) 
∆ Systolic BP, 
mm Hg. 
18,2±6,5 17,8±7,8 16,1±7,4 19,4±7,2 18,2±7,1 17,4±7,4 
∆ Diastolic 
BP, mm Hg 
11,4±6,2 11,1±5,2 9,5±6,4 9,5±5,4 9,2±5,3 9,5±4,0 
∆ HR, 
beats/min 
7,2±2,5 7,1±2,6 5,4±2,1 9,9±5,6 9,2±5,1 8,4±4,8 
Note: Differences between groups on relevant allelic variants in all hemodynamic parameters 
As can be seen from the table, or inside the 
group by genotype (G;G), (G;C), (C;C) nor between 
the groups on the respective allelic variants of 
statistically significant differences was not received 
(in all cases, the values of the two-way p > 0.05). In 
comparison of obtained results with available in the 
world literature it should be noted that in some cases 
carriers of the negative allele (C;C), this 
polymorphism was associated with increased activity 
of CYP2D6, resulting in decrease in the effect of 
metabolizing them drugs, while in others such laws 
has not been established. 
In lipidological and biochemical part of the 
study evaluated the effect of the lipid-lowering and 
antihypertensive drug therapy on lipid and 
carbohydrate metabolism, levels of blood creatinine. 
As a result of 6-months therapy in both groups 
pharmacological intervention negative impact on the 
levels of glucose and blood creatinine was not 
observed, on the contrary, tended to their 
improvement. The main indicators of lipid spectrum 
were improved (table 6). 
Table 6 
Dynamics of the main biochemical parameters in the 
intervention groups (M±SD, n=200) 
Parameter 1st group (n=100) 2nd group (n=100) 
Total 
cholesterol, 
mmol/l 
5,37±0,71 4,62±0,63* 5,32±0,82 4,58±0,62* 
HDL, 
mmol/l 
1,57±0,41 1,82±0,45 1,6±0,47 1,77±0,43 
LDL, 
mmol/l 
3,18±0,66 2,33±0,76* 3,03±0,84 2,36±0,67* 
Creatinine, 
mmol/l 
85,5±9,8 87,0±7,7 89,3±9,9 88,4±9,3 
Glucose, 
mmol/l 
5,04±0,5 4,88±0,5 5,13±0,5 5,04±0,4 
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Comparative analysis of the effectiveness of lipid-
lowering intervention in patients in both  groups are 
presented in table 7. Note worthy adequate lipid-
lowering effect on indicators of atherogenic fractions of 
lipoproteins of blood serum and the absence of 
statistically significant differences between the groups. 
Table 7 
Comparative analysis of the effectiveness of lipid-
lowering intervention in patients with concomitant 
cardiac pathology (M±SD, n =200) 
Parameters 
1st group 
(n=100) 
2nd group (n=100) 
lowering  of total 
cholesterol, % 
13,4±2,2 13,9±2,26 
increase  
HDL cholesterol, % 
15,9±4,6 12,9±4,7 
reduction  
LDL cholesterol, % 
26,7±5,3 24,8±4,6 
To assess the impact of genetic factors on the 
efficacy of lipid-lowering correction seemed 
interesting to assess the impact of protein gene 
polymorphism, transporting cholesterol esters CETP 
rs4783961 on the effectiveness of lipid-lowering 
correction in the groups of intervention. 
This polymorphism choise is based on two 
premises: first, a sufficient frequency of "minor" 
allele, and secondly, available in the world literature 
data, not only about its effect on the lipid spectrum, 
but also on the risk of early development of non-fatal 
myocardial infarction [23, 24]. The results of the 
analysis of the influence of this allele on the basic 
parameters of lipid-transport system in patients in the 
intervention groups are presented in table 8. 
Table 8 
Dynamics of the main biochemical parameters depending on the carriage of allelic variants of the gene CETP 
(rs4783961), (M±SD, n = 200) 
Group 1st group (n=100) 2nd group (n=100) 
Allele 
rs4783961 
 (А;A), 
(n=22) 
rs4783961 
(А;G), (n=56) 
rs4783961 
(G;G), 
(n=22) 
rs4783961 (А;A), 
(n=23) 
rs4783961 (А;G), 
(n=53) 
rs4783961 
(G;G), 
(n=26) 
lowering  of total 
cholesterol, % 
13,4±2,2 13,8±2,5 12,9±2,1 13,9±2,3 13,5±2,4 12,9±1,9 
increase  
HDL cholesterol, 
% 
15,9±4,6 15,1±4,3 10,1±4,0* 12,9±4,7 12,1±4,3 9,3±4,0* 
reduction  
LDL cholesterol, % 
26,7±5,3 26,2±5,1 25,4±5,2 24,8±4,6 24,1±4,3 25,2±4,1 
Differences within 
groups for LDL 
cholesterol, p 
(А;A) / (А;G): p>0,05 (н/д) (А;A) / (А;G): p>0,05 (н/д) 
(А;G) / (G;G): p>0,05 (н/д) (А;G) / (G;G): p>0,05 (н/д) 
(А;A) / (G;G): p>0,05 (н/д) (А;A) / (G;G): p>0,05 (н/д) 
Differences within 
groups for HDL 
cholesterol, p 
(А;A) / (А;G): p>0,05 (н/д) (А;A) / (А;G): p>0,05 (н/д) 
(А;G) / (G;G): p>0,05 (н/д) (А;G) / (G;G): p>0,05 (н/д) 
(А;A) / (G;G): p<0,05 (А;A) / (G;G): p<0,05 
Note: Differences between groups on the relevant alleles in the compared indicators were not identified. 
As can be seen from the table, statistically 
significant differences in dynamics of indicators of 
HDL cholesterol have been identified as in the 1st 
and in the 2nd group. The carriers of the genotype 
(G;G), there was statistically significantly smaller 
increase of HDL cholesterol (10,1±4.0% in the first 
group, and 9.3±4.0% in the second group, 
respectively) compared with carriers of other alleles 
(15,9±4,6% and 15.1±4.3% for the allele (A;A) and 
(A;G), respectively in the first group, and 12.9±4.7% 
and 12,1±4.3% for the allele (A;A) and (A;G), 
respectively in the second group). These differences 
are a subject for further study, make genotyping for 
this polymorphism is clinically significant, and 
confirm hypotheses about the influence of this 
polymorphism on the risk of development of 
cardiovascular complications, since HDL cholesterol 
is "anti-risk” of coronary pathology. 
In the part devoted to the assessment of the 
dynamics of vascular age, we obtained the following 
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results. As among men, and among women the 
estimated vascular age and 5-year risk of cardiovascular 
complications significantly decreased at 6 months 
treatment, with statistically significant gender 
differences were not found, so the following is 
summary data for groups in general. Comparative 
analysis of dynamics of parameters of vascular age and 
5-year cardiovascular risk are presented in table 9.  
Table 9 
Dynamics of indices of vascular age and 5-year cardiovascular risk in the intervention groups (M±SD, n =200) 
Parameters 
1st group (n=100) 2nd group (n=100) 
p 
1-2 
At baseline After 6 months At baseline After 6 months 
Vascular age 
61,0 
[55,8;66,0] 
54,0** 
[50,0;62,0] 
60,0 
[52,8;65,0] 
54,0** 
[49,5;61,0] 
ns 
5-year risk (abs.%) 
2,7 
[2,3;4,0] 
2,0** 
[1,6;2,4] 
3,0 
[2,1;3,6] 
2,4** 
[1,5;3,0] 
ns 
Notes: 1) abs.% – absolute ( % ) risk reduction, 2) the statistical significance of differences of indicators in dynamics in 
the same group: * p<0.05, * * p<0,01, 3) p 1-2 – intergroup differences in the indices, ns – the difference was not statistically 
significant. 
In the analysis of the parameters of vascular age 
as an integral indicator of the state of the 
cardiovascular system, as well as a 5-year 
cardiovascular risk on the background of the 
conducted pharmacotherapy there is a strong positive 
trend. However, statistically significant differences 
between 1-St and 2-nd groups were not detected 
Conclusion. Thus, the results of these studies 
point to the pronounced clinical efficacy of combined 
therapy in both groups, patients with concomitant 
cardiac pathology in the form of improved 
hemodynamic parameters (significant decrease in 
systolic and diastolic BP), parameters of the lipid 
spectrum, glucose and blood creatinine and 
significant decrease of the indicator "vascular age" 
and the 5-year cardiovascular risk. All this 
emphasizes the necessity for an integrated approach 
in the treatment of comorbid cardiovascular 
pathology, primarily due to correction of modifiable 
risk factors. 
On the other hand, the data obtained on the 
contribution of pharmacogenetic factors in the 
variation of the effect of drugs, emphasize that in 
some cases in real life, this influence is not clinically 
significant (as it was shown for ACE-I and beta-
blocker), others may have a clinical value as it was 
shown for lipid-lowering correction). The above 
confirms the necessity for further research in this 
direction. 
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